Ignite Creation Date:
2025-12-24 @ 12:07 PM
Ignite Modification Date:
2026-01-27 @ 2:37 AM
Study NCT ID:
NCT03425461
Status:
TERMINATED
Last Update Posted:
2021-04-02
First Post:
2018-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Melanoma | View |
| None | Stage III Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIA Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIB Cutaneous Melanoma AJCC v7 | View |
| None | Stage IIIC Cutaneous Melanoma AJCC v7 | View |
| None | Stage IV Cutaneous Melanoma AJCC v6 and v7 | View |
Keywords: